D.E. Shaw & Co
ENZ

D.E. Shaw & Co’s Enzo Biochem, Inc. ENZ Stock Holding History

D.E. Shaw & Co’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,275
Closed -$38K – 4559
2020
Q4 		$38K Sell
15,275
-1,816
-11% -$3.96K ﹤0.01% 3855
2020
Q3 		$36K Sell
17,091
-47,326
-73% -$112K ﹤0.01% 3756
2020
Q2 		$144K Sell
64,417
-23,643
-27% -$60.8K ﹤0.01% 3843
2020
Q1 		$223K Sell
88,060
-60,039
-41% -$147K ﹤0.01% 3601
2019
Q4 		$390K Sell
148,099
-12,557
-8% -$37.5K ﹤0.01% 3519
2019
Q3 		$578K Sell
160,656
-97,140
-38% -$344K ﹤0.01% 3144
2019
Q2 		$869K Sell
257,796
-36,157
-12% -$127K ﹤0.01% 2760
2019
Q1 		$802K Buy
293,953
+55,588
+23% +$182K ﹤0.01% 2731
2018
Q4 		$663K Sell
238,365
-5,918
-2% -$19.4K ﹤0.01% 2925
2018
Q3 		$1.01M Buy
244,283
+9,352
+4% +$42.5K ﹤0.01% 2704
2018
Q2 		$1.22M Sell
234,931
-4,076
-2% -$24.8K ﹤0.01% 2569
2018
Q1 		$1.31M Buy
239,007
+89,740
+60% +$632K ﹤0.01% 2316
2017
Q4 		$1.22M Sell
149,267
-36,219
-20% -$346K ﹤0.01% 2467
2017
Q3 		$1.94M Sell
185,486
-73,949
-29% -$821K ﹤0.01% 2047
2017
Q2 		$2.86M Buy
259,435
+66,248
+34% +$617K ﹤0.01% 1739
2017
Q1 		$1.62M Sell
193,187
-9,284
-5% -$65.4K ﹤0.01% 1980
2016
Q4 		$1.41M Buy
202,471
+648
+0.3% +$4.13K ﹤0.01% 2256
2016
Q3 		$1.03M Buy
201,823
+41,762
+26% +$249K ﹤0.01% 2369
2016
Q2 		$956K Sell
160,061
-57,708
-26% -$320K ﹤0.01% 2437
2016
Q1 		$991K Sell
217,769
-38,113
-15% -$170K ﹤0.01% 2361
2015
Q4 		$1.15M Buy
255,882
+136,672
+115% +$577K ﹤0.01% 2547
2015
Q3 		$378K Buy
119,210
+79,775
+202% +$242K ﹤0.01% 3237
2015
Q2 		$119K Sell
39,435
-739
-2% -$2.08K ﹤0.01% 3644
2015
Q1 		$119K Buy
40,174
+8,842
+28% +$28.9K ﹤0.01% 3512
2014
Q4 		$139K Sell
31,332
-14,764
-32% -$70.4K ﹤0.01% 3870
2014
Q3 		$237K Sell
46,096
-40,560
-47% -$216K ﹤0.01% 3810
2014
Q2 		$454K Buy
+86,656
New +$375K ﹤0.01% 3611

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's ENZ Position: Q1 2021 in Review

D.E. Shaw & Co sold out of Enzo Biochem, Inc. (ENZ) in Q1 2021, closing a stake of 15,275 shares — an estimated $38K sold.

D.E. Shaw & Co first reported a position in ENZ in Q2 2014 and held it in 27 quarters. The position peaked at $2.86M in Q2 2017. 82 funds tracked by Wall St. Rank hold ENZ as of Q1 2021.

  • D.E. Shaw & Co reported no remaining Enzo Biochem, Inc. position as of Q1 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,275 Enzo Biochem, Inc. shares in Q1 2021, an estimated $38K.
  • D.E. Shaw & Co first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 27 quarters.
  • D.E. Shaw & Co's Enzo Biochem, Inc. position peaked at $2.86M in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2021.

Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.